Home / Stocks / Medico Remedies Limited
MEDICO

Medico Remedies Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹18.81

Change

+0.57 (3.13%)

Open

₹18.4

Prev. Close

₹18.24

Day High

₹19.11

Day Low

₹18.01

Volume Analysis

Traded

624,549

Delivered

296,384

Delivery %

47.46%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year EPS growth (22.0%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹20.37 ₹19.74 ₹19.27 ₹18.64 ₹18.17 ₹17.54 ₹17.07
Fibonacci ₹19.74 ₹19.32 ₹19.06 ₹18.64 ₹18.22 ₹17.96 ₹17.54
Camarilla ₹19.11 ₹19.01 ₹18.91 ₹18.64 ₹18.71 ₹18.61 ₹18.51

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-61.74%

1 Week

+0.75%

1 Month

-9.48%

3 Months

-55.9%

6 Months

-60.68%

1 Year

-62.83%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

16.03%

Net margin 6.31% × asset turnover 1.02x × equity multiplier 2.49x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Medico Remedies Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 51/100. The strongest factor is Financial Strength (94/100), while Cash Flow (14/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

51/100 — Average

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

94

Growth

81

Cash Flow

14

Corporate Governance

43

Institutional Ownership

20

Business Quality

50

Risk & Volatility

24

Liquidity

29

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Board approved Q2 FY2026-27 standalone results, appointed cost auditor, and issued postal ballot notice on 9 Nov 2026.

Company clarifies share price movement is market-driven and no pending disclosures exist.

Exchange has sought clarification from Medico Remedies Ltd on September 29, 2026 with reference to significant movement in price, in order to ensure that investors …

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 42 30 41 31 39 39 41 38 53 59 57 69 74
Expenses + 39 27 37 28 37 36 35 35 50 54 50 66 71
Operating Profit 3 3 5 3 2 3 7 3 3 4 7 3 3
OPM % 7.25% 9.17% 11.25% 9.16% 6.12% 7.88% 16.13% 7.37% 5.19% 7.38% 12.59% 4.76% 4.27%
Other Income + 1 0 1 0 1 1 0 1 2 1 3 1 1
Interest 0 0 0 0 0 0 0 0 0 0 1 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 3 2 4 2 2 4 6 2 3 4 8 3 3
Tax % 22.61% 30.1% 26.89% 27.06% 27.23% 25.14% 23.9% 25.51% 25.86% 25.07% 29.69% 24.55% 27.22%
Net Profit + 2 1 3 2 2 3 4 2 3 3 6 3 2
EPS in Rs 0 0 0 0 0 0 1 0 0 0 1 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 5 -23 48 -2 -7 33 0 24 34 49 38 81 41

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 51 67 54 61 98 89 122 121 140 145 151 206
Expenses + 48 63 50 58 95 86 117 114 131 132 136 189
Operating Profit 3 4 4 3 3 3 5 7 10 13 15 17
OPM % 6.0% 5.0% 7.0% 6.0% 2.8% 3.2% 4.3% 6.0% 7.0% 9.0% 10.0% 8.0%
Other Income + 0 0 0 1 2 2 1 2 4 2 3 6
Interest 1 1 1 2 1 1 1 1 1 1 1 2
Depreciation 1 1 1 1 2 2 2 2 3 3 3 3
Profit before tax 1 2 2 2 2 2 4 6 10 11 14 18
Tax % 28.0% 40.0% 4.0% 35.0% 28.0% 26.0% 30.0% 26.0% 28.0% 27.0% 25.0% 27.0%
Net Profit + 1 1 2 1 2 2 3 5 7 8 10 13
EPS in Rs 0 0 0 0 0 0 0 1 1 1 1 2
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth 14 31 -18 12 60 -9 38 -1 16 3 4 37

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 12 13 13 23 24 26 28 20 27 36 46 59 64
Borrowings + 8 14 19 13 14 14 15 13 10 8 14 19 32
Other Liabilities + 14 17 13 20 35 32 28 28 34 36 43 59 89
Total Liabilities 36 46 48 59 76 75 76 77 87 96 120 153 202
Fixed Assets + 8 7 7 7 12 13 15 18 22 21 21 20 20
CWIP 0 0 3 4 1 2 0 0 0 0 0 3 4
Investments 1 1 0 0 0 0 1 0 1 2 2 2 2
Other Assets + 27 38 39 48 63 60 59 59 64 73 96 129 176
Total Assets 36 46 48 59 76 75 76 77 87 96 120 153 202
Equity Capital 2 2 3 4 4 4 4 17 17 17 17 17 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + — — -3 5 5 1 -11 6 8 2 5 6
Cash from Investing Activity + — — -3 -5 -4 -3 -17 -2 -7 -3 -3 -5
Cash from Financing Activity + — — 6 -1 -1 3 18 -6 -2 0 -1 -1
Net Cash Flow — — 0 0 0 0 -10 -2 0 -1 1 1
Free Cash Flow — — -4 3 1 -2 -28 3 2 0 2 1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — -68 162 198 53 -198 104 111 43 58 64

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.34% → 61.38%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 25.36% 25.63% 25.46% 25.47% 32.0% 36.08% 37.33% 38.3% 38.13% 38.6% 38.55% 38.02%
Promoters 73.34% 73.34% 73.34% 73.34% 66.83% 63.79% 62.59% 61.38% 61.38% 61.38% 61.38% 61.38%
FII 1.29% 0.29% 0.22% 0.22% 0.39% 0.11% 0.07% 0.3% 0.49% 0.03% 0.08% 0.6%
DII 0.0% 0.74% 0.97% 0.97% 0.78% 0.01% 0.01% 0.01% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Medico Remedies Limited (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Medico Remedies Limited?

Frequently Asked Questions about Medico Remedies Limited

Community Sentiment

What are other investors saying about Medico Remedies Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.